N-(4-bromo-2-fluorophenyl)-6-d3-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | 1174683-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-bromo-2-fluorophenyl)-6-d3-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
• 英文别名: N-(4-bromo-2-fluorophenyl)-7-[(1-methylpiperidin-4-yl)methoxy]-6-(trideuteriomethoxy)quinazolin-4-amine
• CAS: 1174683-43-2
• 化学式: C₂₂H₂₄BrFN₄O₂
• 分子量: 478.337
• InChiKey: UHTHHESEBZOYNR-BMSJAHLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• VANDETANIB DERIVATIVES
  申请人：Tung Roger

  公开号：US20110117084A1

  公开（公告）日：2011-05-19

  This invention relates to novel quinazoline derivatives and their acceptable acid addition salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibitory activity against the VEGF receptor tyrosine kinase.

  本发明涉及新型喹噁啉衍生物及其可接受的酸盐。本发明还提供了包含本发明化合物的组合物，并且使用这种组合物治疗通过抑制VEGF受体酪氨酸激酶活性有益治疗的疾病和病症的方法。
• US8609673B2
  申请人：——

  公开号：US8609673B2

  公开（公告）日：2013-12-17
• [EN] VANDETANIB DERIVATIVES<br/>[FR] DÉRIVÉS DE VANDETANIB
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2009094210A1

  公开（公告）日：2009-07-30

  This invention relates to novel quinazoline derivatives and their acceptable acid addition salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibitory activity against the VEGF receptor tyrosine kinase.